S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Price, News & Analysis

$2.66
-0.12 (-4.32%)
(As of 03/28/2024 ET)
Today's Range
$2.65
$2.98
50-Day Range
$2.14
$3.50
52-Week Range
$1.24
$10.20
Volume
192,342 shs
Average Volume
240,452 shs
Market Capitalization
$68.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.38

Leap Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
327.6% Upside
$11.38 Price Target
Short Interest
Healthy
4.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.32mentions of Leap Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.08) to ($1.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.66 out of 5 stars

Medical Sector

491st out of 938 stocks

Pharmaceutical Preparations Industry

221st out of 417 stocks

LPTX stock logo

About Leap Therapeutics Stock (NASDAQ:LPTX)

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

LPTX Stock Price History

LPTX Stock News Headlines

5 Best Biotech Penny Stocks to Invest In
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
LPTX Apr 2024 5.000 call
LPTX Mar 2024 7.000 call
LPTX Jun 2024 1.000 call
LPTX Mar 2024 1.000 call
Recap: Leap Therapeutics Q3 Earnings
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
54
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.38
High Stock Price Target
$17.50
Low Stock Price Target
$7.00
Potential Upside/Downside
+327.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-81,410,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$2.35 per share

Miscellaneous

Free Float
22,707,000
Market Cap
$68.10 million
Optionable
Optionable
Beta
0.58
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Douglas E. Onsi J.D. (Age 55)
    CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
    Comp: $1.04M
  • Mr. Augustine J. Lawlor (Age 67)
    Chief Operating Officer
    Comp: $713.57k
  • Dr. Cynthia A. Sirard (Age 54)
    Chief Medical Officer
    Comp: $708.64k
  • Dr. Jason S. Baum Ph.D. (Age 45)
    Chief Scientific Officer
  • Mr. Mark O'Mahony (Age 53)
    Chief Manufacturing Officer
  • Ms. Christine M. Granfield (Age 56)
    VP and Head of Regulatory Affairs & Quality

LPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued twelve-month price targets for Leap Therapeutics' shares. Their LPTX share price targets range from $7.00 to $17.50. On average, they expect the company's stock price to reach $11.38 in the next twelve months. This suggests a possible upside of 327.6% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2024?

Leap Therapeutics' stock was trading at $4.15 at the start of the year. Since then, LPTX stock has decreased by 35.9% and is now trading at $2.66.
View the best growth stocks for 2024 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its earnings results on Monday, March, 18th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.10.

When did Leap Therapeutics' stock split?

Leap Therapeutics's stock reverse split on Wednesday, June 21st 2023. The 1-10 reverse split was announced on Wednesday, June 21st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Leap Therapeutics own?
Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.60%), Vanguard Group Inc. (1.60%), Key Client Fiduciary Advisors LLC (0.84%), Price T Rowe Associates Inc. MD (0.47%), Price T Rowe Associates Inc. MD (0.47%) and Northern Trust Corp (0.17%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners